Precision Genomics is combining Artificial Intelligence and machine learning with gene sequencing technology to develop cutting edge mRNA microassays that will measure and monitor biomarkers of chronic inflammation and diseases such as diabetes, cancers, Alzheimer’s and heart disease.
Precision Genomics’ ground-breaking technology, mRNA Inflammatory Index™ (patent pending), measures 48 unique biomarkers at a moment in time for the patient as mRNA, unlike DNA, is constantly changing. Precision Genomics has collected nearly 2000 mRNA samples and continues to collect approximately 100 samples per month from 28 sites. The company is also collecting patient meta data along with biological samples. AI uses algorithms to analyze and draw inferences from patient biomarker results and the vasts amount of patient data being collected.
Samples are collected using a simple cheek swab and can be easily done in a patient’s home or during a doctor’s visit. Non-invasive and easy to use means improved turn-around-time and reduced patient discomfort. Individuals will be able to purchase the test kit and receive results directly. They will also be able to request that results be shared with their physician for review.
The potential for Precision Genomics’ mRNA technology is considerable. Early evidence of our opportunity includes:
- Precision Genomics has received IRB approval for its clinical study for early detection of bladder cancer and bladder cancer recurrence
- FDA encourages the use of biomarkers during numerous phases in the drug development process
- Mountains of research suggest that understanding what part inflammatory processes play during disease progression could lead to identifying potential therapeutic targets and to development of integrated pharmacological approaches that could act at different levels and stages of diseases
Precision Genomics’ growth will result from Direct to Consumer and Direct to Healthcare Professional sales and marketing strategies and from extensive mRNA sample and patient meta data which will have considerable value to the pharmaceutical and biotechnology industries.